Iriny Botrous

This inventor holds 8 USPTO granted patents and 14 published patent applications, plus 2 CIPO patents and 4 EPO patents. Top assignees: Pfizer Corporation, Dart Neuroscience, LLC, Pfizer Products Inc.. Active years: 2007-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Iriny Botrous. Retrieved from https://idiyas.com/inventor/iriny-botrous

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 (Patent Applications = 14)

% Patents Active = 75.0

CIPO Patents = 2 (Patent Applications = 7)

EPO Patents = 4 (Patent Applications = 9)

Average Co-Inventor Count = 6.7

ph-index = 3

Forward Citations = 103(Granted Patents)

Company Filing History:

Dart Neuroscience, LLC

Iambic Therapeutics, Inc.

patent

where one patent can have more than one assignee

Years Active: 2007-2024

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12145948 - Compounds and methods for modulating HER2 (2024-11-19),

2. 12006325 - Substituted furanopyrimidine compounds as PDE1 inhibitors (2024-06-11),

3. 11434247 - Substituted furanopyrimidine compounds as PDE1 inhibitors (2022-09-06),

4. 8999981 - [object Object] (2015-04-07),

5. 8114871 - 3-amido-pyrrolo[3,4-C]pyrazole-5(1H,4H,6H) carbaldehyde derivatives (2012-02-14),

6. 8106197 - Aminoheteroaryl compounds as protein kinase inhibitors (2012-01-31),

7. 7250417 - Arylmethyl triazolo- and imidazopyrazines as c-Met inhibitors (2007-07-31),

8. 7230098 - Aminoheteroaryl compounds as protein kinase inhibitors (2007-06-12),

Title: The Innovative Contributions of Iriny Botrous

Introduction

Iriny Botrous is a notable inventor based in San Diego, California. He has made significant contributions to the field of pharmaceuticals and biotechnology, holding a total of eight patents. His work focuses on developing compounds and methods that have the potential to treat various medical conditions.

Latest Patents

Among his latest patents, Iriny Botrous has disclosed compounds and methods for modulating HER2. These compounds are designed to address disorders mediated by PDE1 activity and dopaminergic signaling. Additionally, he has developed substituted furanopyrimidine compounds as PDE1 inhibitors. These chemical entities have applications in metabolic studies, detection techniques, and therapies for neurological disorders, including dementia and neurodegenerative diseases. His innovations also extend to treating stroke and enhancing cognitive and motor training efficiency.

Career Highlights

Iriny Botrous has worked with prominent companies in the pharmaceutical industry, including Pfizer Corporation and Sugen Incorporated. His experience in these organizations has allowed him to contribute to groundbreaking research and development in drug discovery and therapeutic applications.

Collaborations

Iriny has collaborated with several professionals in his field, including Jingrong Jean Cui and Dilip Ramakant Bhumralkar. These partnerships have fostered a collaborative environment that enhances innovation and the development of new therapeutic strategies.

Conclusion

Iriny Botrous exemplifies the spirit of innovation in the pharmaceutical industry. His patents and collaborations reflect a commitment to advancing medical science and improving patient outcomes. His work continues to inspire future developments in the field.

Profile summary based on public USPTO records.